Abstract
Infectious diseases continue to pose major public health challenges in developed, as well as developing, countries. The European Academies Science Advisory Council aims to integrate multidisciplinary analyses to define priorities for European surveillance of new, growing, or potential threats from antimicrobial resistance, vector-borne disease, and pandemic influenza. There is a concomitant need to apply such knowledge toward the development of improved health care and robust policies. We discuss how translational medicine can bridge these global issues by helping to mobilize resources between academia, industry, health care services, and policy-makers.
Highlights
Infectious diseases continue to pose major public health challenges in developed, as well as developing, countries
In a previous Commentary in Science Translational Medicine [2], we described some of the opportunities and challenges for research and innovation policy in this broad therapeutic area. e European Academies Science Advisory Council (EASAC; www. easac.eu)—an organization created to provide expert, independent scienti c advice to those who make policy in the institutions of the European Union (EU) [2]— has continued to analyze health and innovation policy issues
A rapidly developing, if somewhat controversial, research area with implications for infectious disease diagnosis and control is the use of human genome-wide association studies (GWAS)
Summary
Infectious diseases continue to pose major public health challenges in developed, as well as developing, countries. In the present Commentary, we draw on this resource [3] to discuss some of the latest changes in the infectious disease burden in Europe, including the transmission of new and reemerging pathogens and the dramatic increase in antimicrobial resistance. One consistent theme in the evidence gathered by EASAC is the need to improve standardization of methods for collection, quality control, and interpretation of disease and antimicrobial resistance data.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
